bis(4-fluorophenyl)-3-fluorophenylchloromethane

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: bis(4-fluorophenyl)-3-fluorophenylchloromethane
• 英文别名: 1-[chloro-bis(4-fluorophenyl)methyl]-3-fluorobenzene
• 化学式: C₁₉H₁₂ClF₃
• 分子量: 332.752
• InChiKey: QLWVQIHBVUMERO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氰化亚铜 、 bis(4-fluorophenyl)-3-fluorophenylchloromethane 反应 3.0h， 生成 bis(4-fluorophenyl)-3-fluorophenylacetonitrile
  参考文献：
  名称：

  Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease

  摘要：

  Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of < 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.

  DOI：

  10.1021/jm070663s
• 作为产物：
  描述：

  (3-fluorophenyl)bis(4-fluorophenyl)methanol 在 氯化亚砜 作用下， 生成 bis(4-fluorophenyl)-3-fluorophenylchloromethane
  参考文献：
  名称：

  Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835

  摘要：

  DOI：

文献信息

• TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS
  申请人：Castle Neil A.

  公开号：US20090036538A1

  公开（公告）日：2009-02-05

  The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.

  本发明公开了使用新型钾离子通道抑制剂治疗炎症过程的方法，例如多发性硬化症、胰岛素依赖型（I型）糖尿病、类风湿性关节炎、周围神经炎和肺动脉高压。这些化合物还可用于治疗和预防中风。这些抑制剂对IK1通道具有高度的特异性，并且相对于非氟代同系物具有更高的稳定性。
• Gardos channel antagonists
  申请人：Icagen, Inc.

  公开号：US06288122B1

  公开（公告）日：2001-09-11

  Novel inhibitors of potassium flux are disclosed. The inhibitors show surprising resistance to degradation in biological media and enhanced in vivo half-lives relative to non-fluorine substituted homologues. Methods for the use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

  本文披露了一种新型的钾离子通量抑制剂。这些抑制剂在生物介质中具有惊人的抗降解性能，并且相对于非氟代同系物，具有增强的体内半衰期。这些化合物的使用方法包括治疗镰状细胞贫血，预防红细胞脱水和抑制钾离子通量。
• Treatment methods using triaryl methane compounds
  申请人：Castle A. Neil

  公开号：US20070185209A1

  公开（公告）日：2007-08-09

  The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.

  本发明揭示了使用新型钾通量抑制剂治疗炎症过程，例如多发性硬化症、胰岛素依赖性（I型）糖尿病、类风湿性关节炎、周围神经炎和肺动脉高压。这些化合物还可用于治疗和预防中风。这些抑制剂对IK1通道具有高度特异性，相对于非氟取代同源物具有更高的稳定性。
• Bartroli; Alguero; Boncompte, Arzneimittel-Forschung/Drug Research, 1992, vol. 42, # 6, p. 832 - 835
  作者：Bartroli、Alguero、Boncompte、Forn

  DOI：——

  日期：——
• WO2007/75849
  申请人：——

  公开号：——

  公开（公告）日：——